The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study
Open accessAbstract
BACKGROUND: First metabolomics studies have indicated that metabolic fingerprints from accessible tissues might be useful to better understand the etiological links between metabolism and cancer. However, there is still a lack of prospective metabolomics studies on pre-diagnostic metabolic alterations and cancer risk. METHODS: Associations between pre-diagnostic levels of 120 circulating metabolites (acylcarnitines, amino acids, biogenic amines, phosphatidylcholines, sphingolipids, and hexoses) and the risks of breast, prostate, and colorectal cancer were evaluated by Cox regression analyses using data of a prospective case-cohort study including 835 incident cancer cases. RESULTS: The median follow-up duration was 8.3 years among non-cases and 6.5 years among incident cases of cancer. Higher levels of lysophosphatidylcholines (lysoPCs), and especially lysoPC a C18:0, were consistently related to lower risks of breast, prostate, and colorectal cancer, independent of background factors. In contrast, higher levels of phosphatidylcholine PC ae C30:0 were associated with increased cancer risk. There was no heterogeneity in the observed associations by lag time between blood draw and cancer diagnosis. CONCLUSION: Changes in blood lipid composition precede the diagnosis of common malignancies by several years. Considering the consistency of the present results across three cancer types the observed alterations point to a global metabolic shift in phosphatidylcholine metabolism that may drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Riboli, E., Hunt, K., Slimani, N., Ferrari, P., Norat, T., Fahey, M., Charrondière, U., Hémon, B., Casagrande, C., Vignat, J., et al. (2002) · Public Health Nutrition · doi:10.1079/phn2002394 · Cited by 1,866
Self-citationBatch effect removal methods for microarray gene expression data integration: a survey
Lazar, C., Meganck, S., Taminau, J., Steenhoff, D., Coletta, A., Molter, C., Weiss-Solis, D. Y., Duque, R., Bersini, H., & Nowe, A. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs037 · Cited by 333
The InterAct Consortium (2011) · Diabetologia · doi:10.1007/s00125-011-2182-9 · Cited by 208
Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis
Vouk, K., Hevir, N., Ribič-Pucelj, M., Haarpaintner, G., Scherb, H., Osredkar, J., Möller, G., Prehn, C., Rižner, T. L., & Adamski, J. (2012) · Human Reproduction · doi:10.1093/humrep/des152 · Cited by 143
Floegel, A., Drogan, D., Wang-Sattler, R., Prehn, C., Illig, T., Adamski, J., Joost, H.-G., Boeing, H., & Pischon, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021103 · Cited by 135 · cited 1×
“A limitation of our study is that only a single blood sample was available; however, reasonable mid-term reliability of metabolite levels over time has been demonstrated in reproducibility studies [34–37].”
Background
Cited by
The mechanisms of lysophosphatidylcholine in the development of diseases
Liu, P., Zhu, W., Chen, C., Yan, B., Zhu, L., Chen, X., & Peng, C. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117443 · Cited by 579
Siskos, A. P., Jain, P., Römisch-Margl, W., Bennett, M., Achaintre, D., Asad, Y., Marney, L., Richardson, L., Koulman, A., Griffin, J. L., et al. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02930 · Cited by 269
Metadata
- Authors
- Kühn, T., Floegel, A., Sookthai, D., Johnson, T., Rolle-Kampczyk, U., Otto, W., von Bergen, M., Boeing, H., & Kaaks, R.
- Venue
- BMC Medicine
- Published
- 2016-01-28
- Volume
- 14
- Issue
- 1
- Pages
- 13-13
- ISSN
- 1741-7015 (ISSN-L)
- OpenAlex
- W2262309062
- Cited by
- 241
- References
- 5
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study. https://app.cochat.ai/papers/10.1186/s12916-016-0552-3
- The paper
- Kühn, T., Floegel, A., Sookthai, D., Johnson, T., Rolle-Kampczyk, U., Otto, W., von Bergen, M., Boeing, H., & Kaaks, R. (2016). Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study. BMC Medicine. https://doi.org/10.1186/s12916-016-0552-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.